[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
D000328:Adult; D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D004296:Dopa Decarboxylase / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage*; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide; D004296:Dopa Decarboxylase